Evidence map›Paper›PMID 35523464›Full record

Observational studyArchivos de la Sociedad Espanola de Oftalmologia2022

Results of the treatment of patients with exudative AMD during the COVID-19 pandemic.

C Arruabarrena, R Montejano-Milner, F de Aragón, G Allendes, M A Teus

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in Archivos de la Sociedad Espanola de Oftalmologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

C ArruabarrenaServicio de Oftalmología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Clínica Novovisión Madrid, Madrid, Spain. Electronic address: carruabarrenas@gmail.com.
R Montejano-MilnerServicio de Oftalmología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Clínica Novovisión Madrid, Madrid, Spain.
F de AragónServicio de Oftalmología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain.
G AllendesServicio de Oftalmología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain.
M A TeusServicio de Oftalmología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain; Clínica Novovisión Madrid, Madrid, Spain; Facultad de Medicina, Universidad de Alcalá de Henares, Alcalá de Henares, Spain.
Clínica Rementería · ESHospital Universitario Príncipe de Asturias · ESUniversidad de Alcalá · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveThe SARS-CoV-2 pandemic has caused chaos in all health systems on the planet. It has been difficult to cope with COVID 19, but also to maintain the activity in other specialties. In ophthalmology, the scientific societies recommended providing urgent care, including the intravitreal treatment of patients with active neovascular age-related macular degeneration (AMD), since a delay in treatment implies a potential loss of visual acuity (VA). The main objective of this study was to measure the impact of the coronavirus lockdown on the activity and visual results in patients with neovascular AMD in Area 3 of Madrid. MATERIAL AND

methodA retrospective observational study was conducted of all patients with neovascular AMD who attended a consultation and/or received intravitreal treatment in the 3 months before the lockdown.

resultsIn the 3 months before the lockdown, 144 patients with neovascular AMD were treated, of whom only 51 attended a consultation during the lockdown and, at 6 months after it, only 117 patients had resumed their follow-up. Mean VA before the lockdown was 58.0 ± 23.7 letters and was statistically significantly reduced to 53.0 ± 27.1 letters at 6 months after the lockdown. We also observed a significant decrease in the number of visits during the lockdown, despite the security measures implemented.

conclusionsOur study shows that patients with neovascular AMD have had a statistically significant decrease in VA due to the lockdown. A VA of almost 58 letters was reduced to 53 at 6 months after the lockdown. The percentage of patients who lost 15 or more letters doubled. We observed a 63.3% loss of temporary follow-up during the lockdown and a 14.58% loss of permanent follow-up at 6 months after the lockdown.

Indexed as

COVID-19Wet Macular DegenerationAngiogenesis InhibitorsCommunicable Disease ControlHumansIntravitreal InjectionsPandemicsSARS-CoV-2Vascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsVascular Endothelial Growth Factor AAge related macular degenerationAntiangiogénicosAnti-VEGFCovidDegeneración macular asociada a la edadLockdownPandemia

Identifiers

PMID35523464
PMCPMC8863427
OpenAlexW4226450886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.